BioCryst Pharmaceuticals (BCRX) Edging Higher on Additional NIAID Funding

BioCryst Pharmaceuticals, Inc. (BCRX) shares are edging higher in early trading on Wednesday following news that $4.1 million additional National Institute of Allergy and Infectious Diseases [NIAID] funding will be given to the company to advance development of BCX4430 to treat hemorrhagic fever virus diseases. BioCryst also announced that NIAID has exercised additional options to […] View the full post at: BioCryst Pharmaceuticals (BCRX) Edging Higher on Additional NIAID Funding Related posts: General Motors Borrows $4 bln in Additional Federal Aid Do the Benefits of Preventative Care Justify the Higher Spending? Global Inflation Creeping Higher